ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Bringing confident diagnosis to more patients at low cost: Philips launches new AI-enabled CT 5300 at #ECR2024

February 29, 2024

  • New CT 5300 system provides more accurate and reliable imaging results to better manage increase in complex cardiac cases where precise patient diagnosis is crucial
  • Philips’ latest innovation leverages the power of AI at every stage in CT scanner operation to enhance productivity and diagnostic capabilities of high-throughput, short-staffed radiology departments

Amsterdam, the Netherlands and Vienna, Austria – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Philips CT 5300 system equipped with advanced AI capabilities designed to be used for diagnosis, interventional procedures and screening. The flexible X-ray CT system increases diagnostic confidence, streamlines workflow efficiency, and maximizes system up-time, helping to improve patient outcomes and department productivity. As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare.

CT plays an important role in the diagnosis of cardiac disease. Recent research indicates a “CT first” strategy to triage patients presenting with chest pain with undiagnosed coronary artery disease has been shown to improve patient care by helping them avoid more invasive procedures [1]. However, a lack of availability of high-quality CT systems, or physicians qualified to read cardiac CT exams, often prevents this approach. The Philips CT 5300 system meets advanced diagnostic imaging requirements for cardiac care patient guidelines, as well as for other challenging areas such as trauma care and interventional procedures.

The system also integrates virtual tools for real-time collaboration and clinical/technical support, which can be instrumental in overcoming challenges related to increased patient caseloads, complex cases, staff shortages, and budget constraints. By bringing clinical expertise and functionality previously associated with high-end scanners into a more affordable, versatile system, Philips is committed to making advanced medical technology more accessible to more patients. Emphasizing lifetime value and sustainability, the CT 5300 is designed to lower energy consumption.

The new CT 5300 system is already installed at several European hospitals and has been well-received. “CT 5300 offers CT imaging from head to toe, combined with high-end functionality such as coronary angiography, delivering an extremely broad spectrum of applications, helping us to better manage increased volumes of patients,” said Dr. Hilmar Kühl, Head of Radiology at St. Bernhard-Hospital Kamp-Lintfort, Germany. “With this latest system from Philips, we see an improvement in image quality with Precise Imaging, and for the first time, we can now visualize cardiac anatomy by using Precise Cardiac nearly artifact-free, which is very valuable to help improve cardiac care for our patients.”

“We listened to radiologists about the issues they face every day and what they wanted out of a next-generation CT system. We then combined the latest imaging and AI technologies to meet their needs and created a system that delivers next-level diagnostic confidence, empowers workflows, and ensures lifetime value,” said Frans Venker, Business Leader of CT at Philips. “We’ve leveraged AI in virtually every aspect of the CT 5300, freeing both CT technicians and radiologists from tedious, time-consuming tasks so they can spend more time focused on their patients.”

Next-level diagnostic confidence and workflow efficiency
The new system introduces Nanopanel Precise, the industry’s first detector built from the ground up specifically for AI-based reconstruction. This brand-new detector leverages the full capabilities of Philips Precise Image reconstruction software to deliver high-quality images at much lower radiation dose. At 80% lower dose, Precise Image achieves up to 85% lower noise and 60% better low-contrast detectability than conventional image reconstruction [2]. Combined with Precise Cardiac motion compensation, Precise Image makes the CT 5300 particularly suitable for high-quality, motion-free, cardiac imaging [3] in patients with high heart rates or heart-rate variability.

Where additional expertise or technical support is required during an exam, the new system also features virtual tools like Philips CT Collaboration Live [4] to facilitate remote collaboration, education, and training. More time spent with patients means a better patient experience, while greater productivity and ease of working enhance the operator experience to help mitigate staff shortages and overload.

[1] Markus Scherer, MD, Atrium Health-Sanger Heart and Vascular Institute, Charlotte, NC. The study findings were presented February 1, 2024 at the American College of Cardiology (ACC) Cardiovascular Summit in Washington, DC.
[2] Lower image noise, improved low-contrast detectability, and/or dose reduction were tested using reference body protocols. All metrics were tested on phantoms. Low-contrast detectability tests were performed using 1.0 mm slices, and tested on the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using an auto tool “CHO” (Channelized Hotelling Observer). Data on file. Philips White Paper ‘Basic IMR testing, considerations and image quality trends’.
https://www.philips.co.uk/c-dam/b2bhc/gb/resource-catalog/landing/brightontender/ct-imr-white-paper-lr.pdf
[3] Precise Image for cardiac scans is 510(k) pending –not available for sale in the USA.
[4] 510(k) pending –not available for sale in the USA. Not available in all geographies.

For further information, please contact:

Kathy O’Reilly
Philips Global External Relations
Tel.: +1 978-221-8919
E-mail: kathy.oreilly@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring, and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  227.49
+0.52 (0.23%)
AAPL  268.61
-0.20 (-0.07%)
AMD  260.02
+0.35 (0.13%)
BAC  52.84
-0.18 (-0.34%)
GOOG  268.34
-1.59 (-0.59%)
META  752.65
+1.83 (0.24%)
MSFT  544.42
+12.90 (2.43%)
NVDA  192.88
+1.39 (0.73%)
ORCL  281.77
+0.37 (0.13%)
TSLA  462.50
+10.08 (2.23%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.